KIF1A.ORG | KIF1A Associated Neurological Disorder
KIF1A.ORG is dedicated to improving the lives of those affected by KIF1A Associated Neurological Disorder and accelerating research to find a cure.
KIF1A.ORG is dedicated to improving the lives of those affected by KIF1A Associated Neurological Disorder and accelerating research to find a cure.
We have noticed an unusual activity from your IP 199.16.157.180 and blocked access to this
Judith Luker discusses the sudden unexpected death in epilepsy communication gap and the importance of physician-patient conversations.
Ponni Subbiah, MD, MPH, Senior Vice President Global Head of Medical Affairs and Chief Medical Officer, Acadia Pharmaceuticals, discusses trofinetide for the treatment of Rett…
Dr. Varshavsky-Yanovsky discusses the safety of elranatamab in Black or African-American patients with multiple myeloma.
We have noticed an unusual activity from your IP 199.16.157.180 and blocked access to this
Barbara Burton, MD, Northwestern University, discusses enzyme replacement therapy in patients with mucopolysaccharidosis (MPS) IVA.
We have noticed an unusual activity from your IP 199.16.157.180 and blocked access to this
Dr. Smith-Whitley, pediatric hematologist at the Children’s Hospital of Philadelphia, discusses the advances in sickle cell disease.
For hematologic malignancy (HM) patients admitted to the ICU, survival is 49 percent at seven days and 21 percent at 12 months.
Incremental cost-effectiveness ratios were $126,000 and $281,000 per QALY for two simulation models from a societal perspective.